mexiletine has been researched along with Electrocardiogram QT Prolonged in 76 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a 28-year-old female patient with congenital type 2 long QT syndrome (LQTS) in which mexiletine shortened corrected QT interval (QTc) and effectively prevented refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF)." | 8.12 | Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome. ( Kai, K; Nakashima, R; Sakamoto, K; Takase, S; Tsutsui, H, 2022) |
| "Experimental studies and clinical reports suggest antiarrhythmic properties of mexiletine in different arrhythmias." | 7.88 | Broad antiarrhythmic effect of mexiletine in different arrhythmia models. ( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Garthmann, J; Köbe, J; Kochhäuser, S; Reinke, F; Wasmer, K, 2018) |
| " This positive lidocaine challenge prompted clinical suspicion of long QT syndrome type 3 (LQT3) and early initiation of mexiletine therapy." | 7.76 | Neonatal long QT syndrome type 3 predicted by positive lidocaine challenge. ( Bailey, A; DI Maria, M; Howley, LW; Schaffer, MS, 2010) |
| "To make a LQT3 model (one form of the long QT syndromes) and to investigate the effect of mexiletine on LQT3." | 7.72 | Effect of mexiletine on long QT syndrome model. ( Li, CZ; Liu, YM; Wang, HW; Yang, ZF; Zheng, YQ, 2003) |
| "Potential utility of mexiletine for the treatment of sparfloxacin-induced long QT syndrome was assessed using the in vivo halothane-anesthetized canine model." | 7.72 | Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Takahara, A, 2003) |
| "The purpose of this study was to test the potential utility of mexiletine for the treatment of drug-induced long QT syndrome in vivo." | 7.70 | Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Tamura, K, 2000) |
| "Flecainide is a potent blocker of the open sodium channel." | 6.70 | Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. ( Atkins, DL; Geletka, RC; Moss, AJ; Windle, JR; Zareba, W, 2001) |
| "Long QT syndrome is a potentially lethal yet highly treatable cardiac channelopathy." | 5.51 | Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome. ( Ackerman, MJ; Bos, JM; Castelletti, S; Crotti, L; Dagradi, F; Rohatgi, RK; Schwartz, PJ, 2019) |
| "We report a 28-year-old female patient with congenital type 2 long QT syndrome (LQTS) in which mexiletine shortened corrected QT interval (QTc) and effectively prevented refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF)." | 4.12 | Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome. ( Kai, K; Nakashima, R; Sakamoto, K; Takase, S; Tsutsui, H, 2022) |
| "Experimental studies and clinical reports suggest antiarrhythmic properties of mexiletine in different arrhythmias." | 3.88 | Broad antiarrhythmic effect of mexiletine in different arrhythmia models. ( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Garthmann, J; Köbe, J; Kochhäuser, S; Reinke, F; Wasmer, K, 2018) |
| "The SCN5A mutation, P1332L, is linked to a malignant form of congenital long QT syndrome, type 3 (LQT3), and affected patients are highly responsive to the Na+ channel blocking drug, mexiletine." | 3.88 | Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease. ( Aschar-Sobbi, R; Backx, PH; Bayer, JD; Chauhan, VS; Gollob, M; Liu, J; Spears, D; Tsushima, R; Vigmond, EJ; Wauchop, M, 2018) |
| " This positive lidocaine challenge prompted clinical suspicion of long QT syndrome type 3 (LQT3) and early initiation of mexiletine therapy." | 3.76 | Neonatal long QT syndrome type 3 predicted by positive lidocaine challenge. ( Bailey, A; DI Maria, M; Howley, LW; Schaffer, MS, 2010) |
| "It has been suggested that both pacing and treatment with mexiletine may reduce torsade de pointes (TdP) arrhythmias in patients with long QT syndrome 3 (LQT3), but it is not fully understood how these interventions could prevent TdP." | 3.72 | Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice. ( Breithardt, G; Carmeliet, E; Carmeliet, P; Fabritz, L; Franz, MR; Haverkamp, W; Kirchhof, P; Nuyens, D; Ottenhof, A; Rossenbacker, T, 2003) |
| "To make a LQT3 model (one form of the long QT syndromes) and to investigate the effect of mexiletine on LQT3." | 3.72 | Effect of mexiletine on long QT syndrome model. ( Li, CZ; Liu, YM; Wang, HW; Yang, ZF; Zheng, YQ, 2003) |
| "Potential utility of mexiletine for the treatment of sparfloxacin-induced long QT syndrome was assessed using the in vivo halothane-anesthetized canine model." | 3.72 | Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Takahara, A, 2003) |
| "The purpose of this study was to test the potential utility of mexiletine for the treatment of drug-induced long QT syndrome in vivo." | 3.70 | Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Tamura, K, 2000) |
| "Recent clinical studies have reported a greater effectiveness of sodium channel block with mexiletine to abbreviate the QT interval in patients with the chromosome 3 variant (SCN5A, LQT3) of the long QT syndrome (LQTS) than those with the chromosome 7 form of the disease (HERG, LQT2), suggesting the possibility of gene-specific therapy for the two distinct forms of the congenital LQTS." | 3.69 | Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome. ( Antzelevitch, C; Antzelevitch, D; Heilmann, C; Sicouri, S, 1997) |
| "Drug-induced long QT syndrome has resulted in many drugs being withdrawn from the market." | 2.82 | Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial. ( Blinova, K; Chan, D; Crumb, WJ; Erato, C; Florian, J; Guo, P; Hong, M; Johannesen, L; Lin, J; Mason, JW; Mutlib, A; Sanabria, C; Stockbridge, N; Stohlman, J; Strauss, DG; Ugander, M; Vicente, J; Waite-Labott, K; Wang, J, 2016) |
| "Flecainide is a potent blocker of the open sodium channel." | 2.70 | Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation. ( Atkins, DL; Geletka, RC; Moss, AJ; Windle, JR; Zareba, W, 2001) |
| "The proband with severe syndactyly and delayed language skills was identified harboring a G406R mutation in CACNA1C." | 2.49 | Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome. ( Gao, Y; Hu, D; Li, C; Li, L; Liu, W; Sun, H; Timothy, KW; Xue, X; Yan, GX; Yuan, Y; Zhang, L, 2013) |
| "In 5 Mexiletine was added, shortening QTc and obtaining the disappearance of the T-wave alternance (TWA) in 3/3." | 1.91 | Autosomal Recessive Long QT Syndrome: Clinical Aspects and Therapy. ( Baban, A; Di Mambro, C; Drago, F; Gnazzo, M; Novelli, A; Paglia, S; Porco, L; Righi, D; Silvetti, MS; Tozzi, AE, 2023) |
| "He shows no structural heart disease, syndactyly, or cranio-facial abnormalities." | 1.62 | Long-term follow-up of a patient with type 2 Timothy syndrome and the partial efficacy of mexiletine. ( Bennis, Y; Berna, P; Hermida, A; Hermida, JS; Jedraszak, G; Kubala, M; Mathiron, A, 2021) |
| "Long QT syndrome is a potentially lethal yet highly treatable cardiac channelopathy." | 1.51 | Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome. ( Ackerman, MJ; Bos, JM; Castelletti, S; Crotti, L; Dagradi, F; Rohatgi, RK; Schwartz, PJ, 2019) |
| "Mexiletine is a Class 1B antiarrhythmic drug that causes the disappearance of T-wave alternans by shortening QTc and peak-to-end of the T wave." | 1.48 | A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T-wave alternans in Timothy syndrome? ( Ergul, Y; Tunca Sahin, G, 2018) |
| "Mexiletine (Mex) has been proposed as a gene-specific therapy for patients with long-QT syndrome type 3 (LQT3) caused by mutations in the cardiac sodium channel gene (SCN5A)." | 1.34 | Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. ( Bloise, R; Liu, N; Napolitano, C; Priori, SG; Ruan, Y, 2007) |
| "Sustained ventricular tachyarrhythmias were induced in 12 of the 56 trials of the VSP." | 1.32 | Ventricular tachyarrhythmias in a canine model of LQT3: arrhythmogenic effects of sympathetic activity and therapeutic effects of mexiletine. ( Aizawa, Y; Chinushi, M; Hosaka, Y; Komura, S; Sugiura, H; Tagawa, M; Washizuka, T, 2003) |
| "Mutations in SCN5A cause arrhythmia syndromes including Brugada syndrome (BrS) and congenital long QT syndrome subtype 3 (LQT3)." | 1.32 | A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. ( Ackerman, MJ; Jahangir, A; Makielski, JC; Munger, TM; Porter, CB; Rok, BA; Tester, DJ; Valdivia, CR, 2004) |
| "d-Sotalol was used to mimic LQT2, whereas ATX-II mimicked LQT3." | 1.30 | Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. ( Antzelevitch, C; Shimizu, W, 1997) |
| "The idiopathic long QT syndrome is a congenital disease characterized by prolongation of the QT interval and by stress-induced syncopal episodes caused by the development of "torsades de pointes"." | 1.29 | The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology. ( Cantù, F; Priori, SG; Schwartz, PJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.32) | 18.7374 |
| 1990's | 9 (11.84) | 18.2507 |
| 2000's | 22 (28.95) | 29.6817 |
| 2010's | 27 (35.53) | 24.3611 |
| 2020's | 17 (22.37) | 2.80 |
| Authors | Studies |
|---|---|
| Cashman, JR | 3 |
| Ryan, D | 2 |
| McKeithan, WL | 3 |
| Okolotowicz, K | 3 |
| Gomez-Galeno, J | 3 |
| Johnson, M | 3 |
| Sampson, KJ | 4 |
| Kass, RS | 4 |
| Pezhouman, A | 1 |
| Karagueuzian, HS | 1 |
| Mercola, M | 3 |
| Wåström, M | 1 |
| Pfammatter, JP | 1 |
| Nakashima, R | 1 |
| Takase, S | 1 |
| Kai, K | 2 |
| Sakamoto, K | 1 |
| Tsutsui, H | 1 |
| Pereira, ENS | 1 |
| Sacilotto, L | 1 |
| Pessente, GD | 1 |
| Guirao, C | 1 |
| Carvalho, MLP | 1 |
| Pereira, ADC | 1 |
| Darrieux, FCDC | 1 |
| Scanavacca, MI | 1 |
| Kim, M | 2 |
| Sager, PT | 2 |
| Tester, DJ | 5 |
| Pradhananga, S | 1 |
| Hamrick, SK | 1 |
| Srinivasan, D | 1 |
| Das, S | 1 |
| Ackerman, MJ | 7 |
| Stutzman, MJ | 1 |
| Gao, X | 1 |
| Ye, D | 1 |
| Zhou, W | 1 |
| Giudicessi, JR | 1 |
| Shannon, K | 1 |
| Shimizu, T | 1 |
| Kawai, S | 1 |
| Kawada, A | 1 |
| Wakamiya, T | 1 |
| Nakano, Y | 1 |
| Watanabe, S | 1 |
| Iwamoto, M | 1 |
| Nasilli, G | 1 |
| Yiangou, L | 1 |
| Palandri, C | 1 |
| Cerbai, E | 1 |
| Davis, RP | 1 |
| Verkerk, AO | 1 |
| Casini, S | 1 |
| Remme, CA | 1 |
| Milani, G | 1 |
| Budriesi, R | 1 |
| Tavazzani, E | 1 |
| Cavalluzzi, MM | 1 |
| Mattioli, LB | 1 |
| Miniero, DV | 1 |
| Delre, P | 1 |
| Belviso, BD | 1 |
| Denegri, M | 2 |
| Cuocci, C | 1 |
| Rotondo, NP | 1 |
| De Palma, A | 1 |
| Gualdani, R | 1 |
| Caliandro, R | 1 |
| Mangiatordi, GF | 1 |
| Kumawat, A | 1 |
| Camilloni, C | 1 |
| Priori, S | 1 |
| Lentini, G | 1 |
| Righi, D | 1 |
| Porco, L | 1 |
| Di Mambro, C | 1 |
| Gnazzo, M | 1 |
| Baban, A | 1 |
| Paglia, S | 1 |
| Silvetti, MS | 1 |
| Novelli, A | 1 |
| Tozzi, AE | 1 |
| Drago, F | 1 |
| Olleik, F | 1 |
| Kamareddine, MH | 1 |
| Spears, J | 1 |
| Tse, G | 1 |
| Liu, T | 1 |
| Yan, GX | 2 |
| Kang, Y | 1 |
| Wei, J | 1 |
| Kim, HJ | 1 |
| Kim, BG | 1 |
| Park, JE | 1 |
| Ki, CS | 1 |
| Huh, J | 1 |
| Youm, JB | 1 |
| Kang, JS | 1 |
| Cho, H | 1 |
| Avidan, OR | 1 |
| Tayebi, K | 1 |
| Del Toro, K | 1 |
| Warrier, R | 1 |
| Hermida, A | 1 |
| Jedraszak, G | 1 |
| Kubala, M | 1 |
| Mathiron, A | 1 |
| Berna, P | 1 |
| Bennis, Y | 1 |
| Hermida, JS | 1 |
| Xu, B | 1 |
| Li, K | 1 |
| Liu, F | 1 |
| Kong, L | 1 |
| Yang, J | 1 |
| Zhou, B | 1 |
| Lv, T | 1 |
| Liu, Y | 1 |
| She, F | 1 |
| He, R | 1 |
| Zhang, P | 2 |
| Yang, Y | 1 |
| Lv, TT | 1 |
| Li, SY | 1 |
| Frommeyer, G | 1 |
| Garthmann, J | 1 |
| Ellermann, C | 1 |
| Dechering, DG | 1 |
| Kochhäuser, S | 1 |
| Reinke, F | 1 |
| Köbe, J | 1 |
| Wasmer, K | 1 |
| Eckardt, L | 1 |
| Tunca Sahin, G | 1 |
| Ergul, Y | 1 |
| Liu, J | 1 |
| Bayer, JD | 1 |
| Aschar-Sobbi, R | 1 |
| Wauchop, M | 1 |
| Spears, D | 1 |
| Gollob, M | 1 |
| Vigmond, EJ | 1 |
| Tsushima, R | 1 |
| Backx, PH | 1 |
| Chauhan, VS | 1 |
| Hu, RM | 1 |
| Li, R | 1 |
| Sun, T | 1 |
| Peterson, BZ | 1 |
| Makielski, JC | 4 |
| Tan, BH | 1 |
| Zhu, W | 1 |
| Mazzanti, A | 3 |
| Voelker, TL | 1 |
| Hou, P | 1 |
| Moreno, JD | 1 |
| Angsutararux, P | 1 |
| Naegle, KM | 1 |
| Priori, SG | 10 |
| Silva, JR | 1 |
| Schwartz, PJ | 8 |
| Sala, L | 1 |
| Bos, JM | 1 |
| Crotti, L | 2 |
| Rohatgi, RK | 1 |
| Castelletti, S | 1 |
| Dagradi, F | 1 |
| Gao, Y | 1 |
| Xue, X | 1 |
| Hu, D | 1 |
| Liu, W | 1 |
| Yuan, Y | 1 |
| Sun, H | 1 |
| Li, L | 1 |
| Timothy, KW | 1 |
| Zhang, L | 1 |
| Li, C | 1 |
| Ma, D | 1 |
| Wei, H | 1 |
| Zhao, Y | 1 |
| Lu, J | 1 |
| Li, G | 1 |
| Sahib, NB | 1 |
| Tan, TH | 1 |
| Wong, KY | 1 |
| Shim, W | 1 |
| Wong, P | 1 |
| Cook, SA | 1 |
| Liew, R | 1 |
| Johannesen, L | 2 |
| Vicente, J | 2 |
| Mason, JW | 2 |
| Erato, C | 1 |
| Sanabria, C | 1 |
| Waite-Labott, K | 1 |
| Hong, M | 1 |
| Lin, J | 1 |
| Guo, P | 1 |
| Mutlib, A | 1 |
| Wang, J | 1 |
| Crumb, WJ | 1 |
| Blinova, K | 1 |
| Chan, D | 1 |
| Stohlman, J | 1 |
| Florian, J | 1 |
| Ugander, M | 1 |
| Stockbridge, N | 1 |
| Strauss, DG | 2 |
| Iyer, V | 1 |
| Roman-Campos, D | 1 |
| Kang, G | 1 |
| Fishman, GI | 1 |
| Funasako, M | 1 |
| Aiba, T | 1 |
| Ishibashi, K | 1 |
| Nakajima, I | 1 |
| Miyamoto, K | 1 |
| Inoue, Y | 1 |
| Okamura, H | 1 |
| Noda, T | 1 |
| Kamakura, S | 1 |
| Anzai, T | 1 |
| Noguchi, T | 1 |
| Yasuda, S | 1 |
| Miyamoto, Y | 1 |
| Fukushima Kusano, K | 1 |
| Ogawa, H | 1 |
| Shimizu, W | 4 |
| Arbelo, E | 1 |
| Sarquella-Brugada, G | 1 |
| Brugada, J | 1 |
| Maragna, R | 2 |
| Faragli, A | 1 |
| Monteforte, N | 1 |
| Bloise, R | 2 |
| Memmi, M | 1 |
| Novelli, V | 1 |
| Baiardi, P | 1 |
| Bagnardi, V | 1 |
| Etheridge, SP | 1 |
| Napolitano, C | 8 |
| Hosseini, M | 1 |
| Pueyo, E | 1 |
| Hameed, A | 1 |
| Yano, M | 1 |
| Nishida, Y | 1 |
| Ishii, T | 1 |
| Takahashi, N | 1 |
| Narahara, H | 1 |
| Howley, LW | 1 |
| DI Maria, M | 1 |
| Bailey, A | 1 |
| Schaffer, MS | 1 |
| Wang, DW | 2 |
| Pedrazzini, M | 1 |
| Cantu, F | 5 |
| De Filippo, P | 1 |
| Kishiki, K | 1 |
| Miyazaki, A | 1 |
| Ikeda, T | 1 |
| George, AL | 2 |
| Aziz, PF | 1 |
| Tanel, RE | 1 |
| Zelster, IJ | 1 |
| Pass, RH | 2 |
| Wieand, TS | 1 |
| Vetter, VL | 1 |
| Vogel, RL | 1 |
| Shah, MJ | 1 |
| Ruan, Y | 2 |
| Liu, N | 2 |
| Bachetti, T | 1 |
| Seregni, M | 1 |
| Morotti, S | 1 |
| Severi, S | 1 |
| Sato, A | 1 |
| Chinushi, M | 4 |
| Suzuki, H | 1 |
| Numano, F | 1 |
| Hanyu, T | 1 |
| Iijima, K | 1 |
| Watanabe, H | 1 |
| Furushima, H | 2 |
| Yoshikane, Y | 1 |
| Yoshinaga, M | 1 |
| Hamamoto, K | 1 |
| Hirose, S | 1 |
| Terrenoire, C | 1 |
| Wang, K | 1 |
| Tung, KW | 1 |
| Chung, WK | 1 |
| Lu, JT | 1 |
| Jean, JC | 1 |
| Omari, A | 1 |
| Kotton, DN | 1 |
| Keller, G | 1 |
| Park, J | 1 |
| Kim, SK | 1 |
| Pak, HN | 1 |
| Bezzina, CR | 1 |
| Tan, HL | 1 |
| Valdivia, CR | 2 |
| Wada, T | 1 |
| McCormack, J | 1 |
| Ye, B | 1 |
| Washizuka, T | 3 |
| Hosaka, Y | 2 |
| Tanabe, Y | 1 |
| Chinushi, Y | 1 |
| Aizawa, Y | 2 |
| Yoshida, H | 1 |
| Sugiyama, A | 3 |
| Satoh, Y | 3 |
| Ishida, Y | 1 |
| Kugiyama, K | 1 |
| Hashimoto, K | 3 |
| Buob, A | 1 |
| Siaplaouras, S | 1 |
| Böhm, M | 1 |
| Jung, J | 1 |
| Tagawa, M | 1 |
| Sugiura, H | 1 |
| Komura, S | 1 |
| Fabritz, L | 1 |
| Kirchhof, P | 1 |
| Franz, MR | 1 |
| Nuyens, D | 1 |
| Rossenbacker, T | 1 |
| Ottenhof, A | 1 |
| Haverkamp, W | 2 |
| Breithardt, G | 1 |
| Carmeliet, E | 1 |
| Carmeliet, P | 1 |
| Wang, HW | 1 |
| Zheng, YQ | 1 |
| Yang, ZF | 1 |
| Li, CZ | 1 |
| Liu, YM | 1 |
| Takahara, A | 1 |
| Rok, BA | 1 |
| Porter, CB | 1 |
| Munger, TM | 1 |
| Jahangir, A | 1 |
| Kehl, HG | 1 |
| Rellensmann, G | 1 |
| Yelbuz, TM | 1 |
| Krasemann, T | 1 |
| Vogt, J | 1 |
| Schulze-Bahr, E | 1 |
| Head, CE | 1 |
| Balasubramaniam, R | 1 |
| Thomas, G | 1 |
| Goddard, CA | 1 |
| Lei, M | 1 |
| Colledge, WH | 1 |
| Grace, AA | 1 |
| Huang, CL | 1 |
| Divekar, A | 1 |
| Soni, R | 1 |
| Tian, XL | 1 |
| Cheng, Y | 1 |
| Zhang, T | 1 |
| Liao, ML | 1 |
| Yong, SL | 1 |
| Wang, QK | 1 |
| El Yaman, M | 1 |
| Perry, J | 1 |
| Locati, EH | 1 |
| Towbin, JA | 1 |
| Keating, MT | 1 |
| Hammoude, H | 1 |
| Brown, AM | 2 |
| Chen, LS | 1 |
| Colatsky, TJ | 1 |
| Yazawa, K | 1 |
| Makita, N | 1 |
| Bennett, PB | 1 |
| Paganini, V | 1 |
| Antzelevitch, C | 3 |
| Sicouri, S | 1 |
| Antzelevitch, D | 1 |
| Heilmann, C | 1 |
| Tamura, K | 1 |
| Windle, JR | 1 |
| Geletka, RC | 1 |
| Moss, AJ | 1 |
| Zareba, W | 1 |
| Atkins, DL | 1 |
| Nishizaki, M | 1 |
| Ashikaga, T | 1 |
| Yamawake, N | 1 |
| Fujii, H | 1 |
| Arita, M | 1 |
| Sumitomo, N | 1 |
| Sakurada, H | 1 |
| Hiraoka, M | 1 |
| Yao, CT | 1 |
| Wang, JN | 1 |
| Tsai, YC | 1 |
| Lin, CS | 1 |
| Wu, JM | 1 |
| Takamizawa, K | 1 |
| Takao, A | 1 |
| Aiba, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical ECG Study to Evaluate Electrophysiological Effects of Potential QT Prolonging Drugs With Novel ECG Biomarkers With Exposure-Response Analysis[NCT05716854] | Phase 1 | 44 participants (Actual) | Interventional | 2023-03-21 | Completed | ||
| Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)[NCT02308748] | Phase 1 | 22 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects[NCT01873950] | Phase 1 | 22 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Long QT Syndrome-Population Genetics and Cardiac Studies[NCT00005176] | 2,125 participants (Actual) | Observational | 1985-08-31 | Completed | |||
| Efficacy of Ranolazine in LQT3 Patients[NCT01648205] | Phase 2 | 25 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evening dose (moxifloxacin+diltiazem) versus afternoon dose (diltiazem alone). (NCT02308748)
Timeframe: 5 weeks
| Intervention | ms (Mean) |
|---|---|
| Moxifloxacin Alone | 29.9 |
| Moxifloxacin + Diltiazem | 31.3 |
After 3rd dose of mexiletine or lidocaine (evening dose) on treatment day when combined with dofetilide to evening dose on dofetilide alone day. (NCT02308748)
Timeframe: 5 weeks
| Intervention | ms (Mean) | |
|---|---|---|
| Placebo corrected change from baseline in QTc | Placebo corrected change from baseline in J-Tpeakc | |
| Dofetilide + Lidocaine | 18 | 3.5 |
| Dofetilide + Mexiletine | 20.4 | 0.8 |
| Dofetilide Alone | 37.9 | 24.0 |
Different post-dose time-points employ different techniques for altering heart rate (leg raises and postural maneuvers). Using the measurements from all the time-points of postural maneuvers, the QT/RR relationship was modeled as a linear relationship between the square root of RR in seconds and QT in seconds and computed on a by subject, treatment and time-point basis. The change in the QT and heart rate relationship was assessed as the difference (mean and 95% CI) between the slopes from the models for each drug vs. placebo. (NCT01873950)
Timeframe: 24 hours
| Intervention | ratio (Mean) |
|---|---|
| Ranolazine 1500mg | 0.01 |
| Dofetilide 500mcg | 0.06 |
| Verapamil HCl 120 mg | 0.02 |
| Quinidine Sulfate 400mg | 0.11 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees per ng/ml (Mean) |
|---|---|
| Dofetilide 500mcg | -3.9 |
| Verapamil HCl 120 mg | 0.4 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in spatial QRS-T angle for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees per mcg/ml (Mean) |
|---|---|
| Ranolazine 1500mg | -1.0 |
| Quinidine Sulfate 400mg | 2.7 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | mV.ns per ng/ml (Mean) |
|---|---|
| Dofetilide 500mcg | 4.0 |
| Verapamil HCl 120 mg | 1.2 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in ventricular gradient for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | mV.ns per mcg/ml (Mean) |
|---|---|
| Ranolazine 1500mg | -0.7 |
| Quinidine Sulfate 400mg | 1.6 |
Compute maximum mean placebo, and baseline-adjusted change for: spatial QRS-T angle (degrees) (NCT01873950)
Timeframe: 24 hours
| Intervention | degrees (Least Squares Mean) |
|---|---|
| Ranolazine 1500mg | -2.2 |
| Dofetilide 500mcg | -4.9 |
| Verapamil HCl 120 mg | -2.4 |
| Quinidine Sulfate 400mg | 3.9 |
Compute maximum mean placebo, and baseline-adjusted change for: ventricular gradient (mV*ms). (NCT01873950)
Timeframe: 24 hours
| Intervention | mV*ms (Least Squares Mean) |
|---|---|
| Ranolazine 1500mg | 2.5 |
| Dofetilide 500mcg | 4.8 |
| Verapamil HCl 120 mg | 4.2 |
| Quinidine Sulfate 400mg | 6.0 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | ms per ng/ml (Mean) | ||||
|---|---|---|---|---|---|
| Change in PR | Change in QTc | Change in QRS | Change in J-Tpeakc | Change in Tpeak-Tend | |
| Dofetilide 500mcg | -0.5 | 73.6 | 0.2 | 39.1 | 34.4 |
| Verapamil HCl 120 mg | 28.7 | 3.9 | 0.3 | -0.7 | 3.6 |
"The exposure response analysis will be performed for each treatment and will use a linear or nonlinear model (as determined by visual inspection) to quantify the relationship between exposure and Baseline and placebo adjusted change from Baseline for each ECG parameter (same as for primary analysis).~The magnitude of change (mean and 95% CI) in QTc for the observed mean Cmax for each drug may be calculated." (NCT01873950)
Timeframe: 24 hours
| Intervention | ms per mcg/ml (Mean) | ||||
|---|---|---|---|---|---|
| Change in PR | Change in QTc | Change in QRS | Change in J-Tpeakc | Change in Tpeak-Tend | |
| Quinidine Sulfate 400mg | 3.0 | 78.9 | 0.4 | 26.1 | 51.2 |
| Ranolazine 1500mg | 4.2 | 12.0 | 0.8 | 0.7 | 10.0 |
Compute maximum mean placebo, and baseline-adjusted change for: PR (ms), QRS (ms), J-Tpeak (ms), Tpeak-Tend (ms) and QTc (ms) (NCT01873950)
Timeframe: 24 hours
| Intervention | ms (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Change in PR interval | Change in QRS duration | Change in J-Tpeakc | Change in Tpeak-Tend | Change in QTc | |
| Dofetilide 500mcg | 2.3 | 1.1 | 39.5 | 40.0 | 79.3 |
| Quinidine Sulfate 400mg | 5.1 | 2.1 | 29.1 | 49.8 | 78.1 |
| Ranolazine 1500mg | 6.5 | 2.7 | 3.3 | 8.8 | 12.6 |
| Verapamil HCl 120 mg | 32.1 | 2.6 | -2.4 | 4.8 | 5.2 |
Change in QTc at 6 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. (NCT01648205)
Timeframe: 1 month to 6 months
| Intervention | miliseconds (Mean) |
|---|---|
| Placebo | 504 |
| Ranolazine at 6 Months | 501 |
Change in QTc at 2 months on ranolazine vs. at 1 month on placebo. This was prespecified outcome. (NCT01648205)
Timeframe: 1 month to 2 months
| Intervention | miliseconds (Mean) |
|---|---|
| Placebo | 503 |
| Ranolazine at 2 Months | 497 |
6 reviews available for mexiletine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Long QT Syndrome; Mexiletine; Myocardium | 2023 |
Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
Topics: Adrenergic beta-Antagonists; Electrocardiography; Flecainide; Humans; Long QT Syndrome; Mexiletine; | 2021 |
Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome.
Topics: Animals; Autistic Disorder; Child, Preschool; DNA Mutational Analysis; Echocardiography, Doppler; El | 2013 |
[Differential diagnosis of idiopathic ventricular fibrillation].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Chromosome Aberrations; Defibrillators, | 2002 |
Molecular biology of the long QT syndrome: impact on management.
Topics: Action Potentials; Adrenergic Antagonists; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artifici | 1997 |
[Possibility of gene-specific treatment for hereditary arrhythmic diseases].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Humans; Ion Channel | 2002 |
4 trials available for mexiletine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
Topics: Adolescent; Adult; Animals; Anti-Arrhythmia Agents; Female; HEK293 Cells; Humans; Ion Channel Gating | 2019 |
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy | 2016 |
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy | 2016 |
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy | 2016 |
Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial.
Topics: Adult; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cross-Over Studies; Diltiazem; Drug Therapy | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Electrocardiographic Biomarkers for Detection of Drug-Induced Late Sodium Current Block.
Topics: Adult; Biomarkers; Calcium Channel Blockers; Cross-Over Studies; Electrocardiography; Ether-A-Go-Go | 2016 |
Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
Topics: Administration, Oral; Adolescent; Adult; Anti-Arrhythmia Agents; Child; Child, Preschool; Drug Monit | 2001 |
66 other studies available for mexiletine and Electrocardiogram QT Prolonged
| Article | Year |
|---|---|
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Behavior, Animal; Cardiac Conduction System Dise | 2021 |
Ten-year-old boy with congenital long QT syndrome type 2 (LQTS2) and life-threatening electrical storm: a case report of successful treatment with mexiletine.
Topics: Arrhythmias, Cardiac; Humans; Isoproterenol; Long QT Syndrome; Male; Mexiletine; Ventricular Fibrill | 2022 |
Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome.
Topics: Adult; Arrhythmias, Cardiac; DNA-Binding Proteins; Electrocardiography; Female; Humans; Long QT Synd | 2022 |
Mexiletine in a Newborn with Type 3 Long QT Syndrome: When Access is Difficult.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Humans; Infant, Newborn; Long QT Syndrome; Mexiletine | 2022 |
SGK1 inhibition attenuates the action potential duration in reengineered heart cell models of drug-induced QT prolongation.
Topics: Action Potentials; Humans; Long QT Syndrome; Mexiletine; Myocytes, Cardiac; Sulfonamides | 2023 |
Functional characterization and identification of a therapeutic for a novel SCN5A-F1760C variant causing type 3 long QT syndrome refractory to all guideline-directed therapies.
Topics: Anti-Arrhythmia Agents; Humans; Infant; Lidocaine; Long QT Syndrome; Mexiletine; NAV1.5 Voltage-Gate | 2023 |
Combined mexiletine and flecainide for severe long QT syndrome type 3.
Topics: Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Electrocardiography; Flecainide; Humans; | 2023 |
Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome.
Topics: Action Potentials; Brugada Syndrome; Cardiac Conduction System Disease; Humans; Long QT Syndrome; Me | 2023 |
hERG stereoselective modulation by mexiletine-derived ureas: Molecular docking study, synthesis, and biological evaluation.
Topics: Animals; Guinea Pigs; Humans; Long QT Syndrome; Mexiletine; Molecular Docking Simulation; Potassium | 2023 |
Autosomal Recessive Long QT Syndrome: Clinical Aspects and Therapy.
Topics: Child; Deafness; Heart Arrest; Humans; Jervell-Lange Nielsen Syndrome; KCNQ1 Potassium Channel; Long | 2023 |
Mexiletine Suppressed Recurrent Ventricular Tachycardia Triggered by Hemodialysis in an Old Patient with LQT2.
Topics: Anti-Arrhythmia Agents; Electrocardiography; Female; Follow-Up Studies; Humans; Kidney Failure, Chro | 2019 |
Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.
Topics: Action Potentials; Adult; Anti-Arrhythmia Agents; Female; Humans; Infant; Long QT Syndrome; Male; Me | 2019 |
Seizure After Minor Head Trauma: A Red Herring?
Topics: Anti-Arrhythmia Agents; Child; Craniocerebral Trauma; Electrocardiography; Electrocardiography, Ambu | 2021 |
Long-term follow-up of a patient with type 2 Timothy syndrome and the partial efficacy of mexiletine.
Topics: Autistic Disorder; Calcium Channels, L-Type; Child; Electrocardiography; Exons; Follow-Up Studies; H | 2021 |
Mexiletine Shortened QT Interval and Reduced Ventricular Arrhythmias in a Pedigree of Type 2 Long QT Syndrome Combined with Left Ventricular Non-Compaction.
Topics: Anti-Arrhythmia Agents; Echocardiography; Electrocardiography; Female; Heart Ventricles; Humans; Lon | 2021 |
Human iPSC-derived cardiomyocytes and pyridyl-phenyl mexiletine analogs.
Topics: Cardiac Conduction System Disease; Dose-Response Relationship, Drug; Humans; Induced Pluripotent Ste | 2021 |
Human-induced pluripotent stem cell-derived cardiomyocytes: Cardiovascular properties and metabolism and pharmacokinetics of deuterated mexiletine analogs.
Topics: Animals; Behavior, Animal; Cells, Cultured; Female; Humans; Induced Pluripotent Stem Cells; Liver; L | 2021 |
Broad antiarrhythmic effect of mexiletine in different arrhythmia models.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disea | 2018 |
A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T-wave alternans in Timothy syndrome?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autistic Disorder; Child, Preschool; Electrocardiograp | 2018 |
Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
Topics: Animals; Brugada Syndrome; CHO Cells; Computer Simulation; Cricetulus; Humans; Long QT Syndrome; Mal | 2018 |
Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
Topics: Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Female; HEK293 Cells; Humans; Infant; Lon | 2018 |
Precision Versus Traditional Medicine-Clinical Questions Trigger Progress in Basic Science.
Topics: Anti-Arrhythmia Agents; Genetic Variation; Humans; Long QT Syndrome; Medicine, Traditional; Mexileti | 2019 |
Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
Topics: Action Potentials; Adolescent; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Child; Dr | 2019 |
Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells.
Topics: Action Potentials; Child; Child, Preschool; Chromosomes, Human, Pair 3; Dermis; Electrocardiography; | 2013 |
Purkinje Cells as Sources of Arrhythmias in Long QT Syndrome Type 3.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Cardiac Conduction System Disease; Heart | 2015 |
Pronounced Shortening of QT Interval With Mexiletine Infusion Test in Patients With Type 3 Congenital Long QT Syndrome.
Topics: Adolescent; Adult; Child; Child, Preschool; Electrocardiography; Female; Humans; Long QT Syndrome; M | 2016 |
Gene-Specific Therapy for Congenital Long QT Syndrome: Are We There Yet?
Topics: Electrocardiography; Female; Genetic Therapy; Heart Rate; Humans; Long QT Syndrome; Male; Mexiletine | 2016 |
Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
Topics: Administration, Oral; Adolescent; Adult; Child; Electrocardiography; Female; Follow-Up Studies; Gene | 2016 |
Reply: Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3?
Topics: Anti-Arrhythmia Agents; Humans; Long QT Syndrome; Mexiletine; Mutation | 2017 |
Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3?
Topics: Anti-Arrhythmia Agents; Cardiac Conduction System Disease; Humans; Long QT Syndrome; Mexiletine; Mut | 2017 |
Long QT syndrome in pregnancy: A successful case of ICD implantation during the prenatal period.
Topics: Adrenergic beta-Antagonists; Adult; Defibrillators, Implantable; Electrocardiography; ERG1 Potassium | 2017 |
Neonatal long QT syndrome type 3 predicted by positive lidocaine challenge.
Topics: Anti-Arrhythmia Agents; Bradycardia; Electrocardiography; Female; Humans; Infant, Newborn; Lidocaine | 2010 |
Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.
Topics: Action Potentials; Anti-Arrhythmia Agents; DNA Mutational Analysis; Dose-Response Relationship, Drug | 2008 |
Congenital long QT syndrome and 2:1 atrioventricular block: an optimistic outcome in the current era.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrioventricular Block; Child; Child, Preschool | 2010 |
Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
Topics: Action Potentials; Anti-Arrhythmia Agents; Cell Line; Computer Simulation; Electrocardiography; Fata | 2010 |
Long QT syndrome with nocturnal cardiac events caused by a KCNH2 missense mutation (G604S).
Topics: Child; Electrocardiography; Epinephrine; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; G | 2012 |
A case of long QT syndrome with triple gene abnormalities: digenic mutations in KCNH2 and SCN5A and gene variant in KCNE1.
Topics: Child; DNA Mutational Analysis; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium | 2013 |
Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics.
Topics: Anti-Arrhythmia Agents; Biophysical Phenomena; Cell Communication; Cells, Cultured; ERG1 Potassium C | 2013 |
A case of Long QT syndrome type 3 aggravated by beta-blockers and alleviated by mexiletine: the role of epinephrine provocation test.
Topics: Adolescent; Adrenergic beta-Antagonists; Defibrillators, Implantable; Diagnosis, Differential; Diagn | 2013 |
Pharmacological rescue of mutant ion channels.
Topics: Anti-Arrhythmia Agents; Humans; Long QT Syndrome; Mexiletine; Mutation; NAV1.5 Voltage-Gated Sodium | 2002 |
A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
Topics: Anti-Arrhythmia Agents; DNA Mutational Analysis; Electrocardiography; Fatal Outcome; Follow-Up Studi | 2002 |
Activation-recovery interval as a parameter to assess the intracardiac ventricular repolarization in patients with congenital long QT syndrome.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Electrophysiologic Techniques, | 2002 |
Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model.
Topics: Action Potentials; Anesthetics, Inhalation; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiac | 2002 |
Ventricular tachyarrhythmias in a canine model of LQT3: arrhythmogenic effects of sympathetic activity and therapeutic effects of mexiletine.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Dogs; Electrocardiography; Heart Rate | 2003 |
Effect of pacing and mexiletine on dispersion of repolarisation and arrhythmias in DeltaKPQ SCN5A (long QT3) mice.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Anim | 2003 |
Effect of mexiletine on long QT syndrome model.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cell Separation; Cnidarian Venoms; Electrocardio | 2003 |
Effects of mexiletine on the canine model of sparfloxacin-induced long QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Blood Pressure; Bundle of | 2003 |
A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs.
Topics: Adolescent; Animals; Arrhythmias, Cardiac; Cell Line; Humans; Long QT Syndrome; Male; Mexiletine; Mu | 2004 |
Images in cardiovascular medicine. Life-threatening neonatal arrhythmia: successful treatment and confirmation of clinically suspected extreme long QT-syndrome-3.
Topics: Bradycardia; Cardiovascular Agents; Electrocardiography; Heart Block; Humans; Infant, Newborn; Infan | 2004 |
Paced electrogram fractionation analysis of arrhythmogenic tendency in DeltaKPQ Scn5a mice.
Topics: Action Potentials; Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Art | 2005 |
Successful parental use of an automated external defibrillator for an infant with long-QT syndrome.
Topics: Anti-Arrhythmia Agents; Combined Modality Therapy; Death, Sudden, Cardiac; Defibrillators; Defibrill | 2006 |
Optical mapping of ventricular arrhythmias in LQTS mice with SCN5A mutation N1325S.
Topics: Animals; Arrhythmias, Cardiac; Asparagine; Cardiac Complexes, Premature; Long QT Syndrome; Mexiletin | 2007 |
Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Topics: Adult; Child; Child, Preschool; Genetic Therapy; Humans; Infant; Ion Channel Gating; Long QT Syndrom | 2007 |
Suppression of atrial fibrillation with mexiletine pharmacotherapy in a young woman with type 1 long QT syndrome.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child; Female; Humans; Long QT Syndrome; Mexiletine | 2008 |
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Topics: Adult; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Case-Control Studies; Chromosome Mapping; | 1995 |
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Topics: Adult; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Case-Control Studies; Chromosome Mapping; | 1995 |
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Topics: Adult; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Case-Control Studies; Chromosome Mapping; | 1995 |
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
Topics: Adult; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Case-Control Studies; Chromosome Mapping; | 1995 |
Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long-QT syndrome.
Topics: Action Potentials; Animals; Cardiac Pacing, Artificial; Cation Transport Proteins; Ether-A-Go-Go Pot | 1996 |
The long QT syndrome: new diagnostic and therapeutic approach in the era of molecular biology.
Topics: Animals; Anti-Arrhythmia Agents; Cardiotonic Agents; Cation Transport Proteins; DNA-Binding Proteins | 1996 |
A molecular basis for the therapy of the long QT syndrome.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Anti-Arrhythmia Agents; Chromosomes, Human, Pa | 1996 |
Pharmacological targeting of long QT mutant sodium channels.
Topics: Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Humans; Long QT Syndrome; Mexiletine; Muta | 1997 |
Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benz(a)Anthracenes; Dogs; Electrocardiography; H | 1997 |
Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dogs; Dose-Response Relationship, Drug; Long QT | 1997 |
Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Dogs; Dose-R | 1998 |
Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: potential utility of mexiletine for the treatment of drug-induced long QT syndrome.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Output; Cardiovascular System; Cisapride | 2000 |
Effects of glucose-induced insulin secretion on ventricular repolarization in patients with congenital long QT syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Blood Glucose; Child; Electrocardiography; Female; G | 2002 |
Congenital long QT syndrome with functionally impaired atrioventricular conduction: successful treatment by mexiletine and propranolol.
Topics: Drug Therapy, Combination; Heart Block; Humans; Infant, Newborn; Long QT Syndrome; Male; Mexiletine; | 2002 |
[Tachycardia in children and its management].
Topics: Child, Preschool; Female; Humans; Infant; Infant, Newborn; Long QT Syndrome; Male; Mexiletine; Pre-E | 1985 |